Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Milestone Pharmaceuticals Inc. (MIST)

NMS · Biotechnology

$1.07-0.06 (-5.31%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$133.2M
P/E (TTM)
EPS
$-0.61
Div Yield
52W Range
$1.00–$3.06
Beta
0.97

Company overview

Next earnings: 2026-08-12(15d)

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

Peers in Biotechnology

All in industry →

Recent press releases

Milestone Pharmaceuticals Inc. has not issued a press release in this window.

SEC filings

All filings →

Milestone Pharmaceuticals Inc. has not filed an SEC document in this window.

Milestone Pharmaceuticals Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
2,810,037 sh-59.7%
781,875 sh-73.7%
1,506,405 sh-46.8%
1,656,821 sh+289.8%
4,118,321 sh-19.6%
1,514,461 sh+127.2%
1,217,130 sh+189.0%
1,249,400 sh+129.3%

People at Milestone Pharmaceuticals Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
NI -$20.8M
06/25
NI -$13.0M
09/25
NI -$11.9M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.12
Prior: $-0.20
Revenue sparkline